SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivo Bio Tech informs about launch of large animal facility

13 Jan 2025 Evaluate
Vivo Bio Tech has informed that it has successfully secured approval from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), obtained funding from a financial institution, and completed the development of a state-of-the-art large animal facility. This advanced 15,000 sq. ft. facility, co-funded through internal accruals and institutional debt, is designed to house, breed, and conduct studies on canines, pigs, mini-pigs, sheep, and goats. Operations have already commenced at the facility, which offers a wide range of services, including Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies. These services are being provided to an expanding list of major pharmaceutical and bio-pharmaceutical companies. This new capability significantly strengthens the company’s existing ecosystem, which encompasses In-vitro and In-vivo Small Animal Studies, Eco-Toxicology, Analytical, and Bio-analytical services. The addition of this large animal facility enables them to deliver comprehensive Investigational New Drug (IND) packages to pharmaceutical and biotech companies worldwide. The company now proudly joins an elite group of Contract Research Organizations (CROs) capable of supporting diverse research and development needs across both large and small animal models. Furthermore, the company is committed to expanding its capabilities to position itself as a joint discovery partner for large pharmaceutical organizations. Future developments will be shared as and when they materialize.

The above information is a part of company’s filings submitted to BSE.

Vivo Bio Tech Share Price

27.99 -0.28 (-0.99%)
12-May-2026 13:09 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1857.10
Dr. Reddys Lab 1279.40
Cipla 1297.15
Zydus Lifesciences 938.00
Lupin 2274.30
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×